Potential Therapeutic Competition in Community-Living Older Adults in the U.S.: Use of Medications That May Adversely Affect a Coexisting Condition
Authors:
Open Access
- 25 February 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (2) , e89447
Abstract
The 75% of older adults with multiple chronic conditions are at risk of therapeutic competition (i.e. treatment for one condition may adversely affect a coexisting condition). The objective was to determine the prevalence of potential therapeutic competition in community-living older adults. Cross-sectional descriptive study of a representative sample of 5,815 community-living adults 65 and older in the U.S, enrolled 2007–2009. The 14 most common chronic conditions treated with at least one medication were ascertained from Medicare claims. Medication classes recommended in national disease guidelines for these conditions and used by ≥2% of participants were identified from in-person interviews conducted 2008–2010. Criteria for potential therapeutic competition included: 1), well-acknowledged adverse medication effect; 2) mention in disease guidelines; or 3) report in a systematic review or two studies published since 2000. Outcomes included prevalence of situations of potential therapeutic competition and frequency of use of the medication in individuals with and without the competing condition. Of 27 medication classes, 15 (55.5%) recommended for one study condition may adversely affect other study conditions. Among 91 possible pairs of study chronic conditions, 25 (27.5%) have at least one potential therapeutic competition. Among participants, 1,313 (22.6%) received at least one medication that may worsen a coexisting condition; 753 (13%) had multiple pairs of such competing conditions. For example, among 846 participants with hypertension and COPD, 16.2% used a nonselective beta-blocker. In only 6 of 37 cases (16.2%) of potential therapeutic competition were those with the competing condition less likely to receive the medication than those without the competing condition. One fifth of older Americans receive medications that may adversely affect coexisting conditions. Determining clinical outcomes in these situations is a research and clinical priority. Effects on coexisting conditions should be considered when prescribing medications.Keywords
This publication has 65 references indexed in Scilit:
- Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional studyThe Lancet, 2012
- A merican G eriatrics S ociety Updated B eers C riteria for Potentially Inappropriate Medication Use in Older AdultsJournal of the American Geriatrics Society, 2012
- Aging with multimorbidity: A systematic review of the literatureAgeing Research Reviews, 2011
- Contribution of Multiple Chronic Conditions to Universal Health OutcomesJournal of the American Geriatrics Society, 2011
- Titration to Target Dose of Bisoprolol vs. Carvedilol in Elderly Patients with Heart Failure: The CIBIS-ELD TrialEuropean Journal of Heart Failure, 2011
- Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based StudyPLOS Medicine, 2009
- Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic reviewBMJ, 2007
- Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control studyBMJ, 2006
- Clinical Practice Guidelines and Quality of Care for Older Patients With Multiple Comorbid DiseasesJAMA, 2005
- The Effects of Cyclooxygenase-2 Inhibitors and Nonsteroidal Anti-inflammatory Therapy on 24-Hour Blood Pressure in Patients With Hypertension, Osteoarthritis, and Type 2 Diabetes MellitusArchives of internal medicine (1960), 2005